Trial Condition(s):
Ophthalmology, Macular Degeneration
A follow-up physician survey to evaluate physician knowledge of safety and safe use information for Aflibercept administered by intravitreal injection in Europe
Bayer Identifier:
20285
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
With this follow up physician survey researcher want to collect the same data from all participants of the study using a highly structured questionnaire. The questionnaire will gather information related to physician characteristics and experience with Aflibercept, as well as assess physicians’ knowledge and understanding of storage and preparation, proper injection technique, and the risks associated with Aflibercept injection into the eye (intravitreal injection). Analysis will be done using descriptive statistics.
Inclusion Criteria
- Has signed informed consent - Is a licensed and practicing ophthalmologist - Has prescribed and/or administered aflibercept to at least one patient in the past 6 months
Exclusion Criteria
- None
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Many locations Many locations, Germany | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Trial Design
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe: A Follow-up Physician Survey
Trial Type:
Observational
Intervention Type:
Other
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Percentage of physicians responding correctly to each individual knowledge questionTimeframe: Up to 1 year
Additional Information
Copyright © Bayer
Powered by
